This study aimed to investigate the clinical effectivity of intravenous methylprednisolone repeated intermittent pulse combined with mycophenolate mofetil in the treatment of newly diagnosed juvenile dermatomyositis.
Reviewed the clinical data of 12 juvenile dermatomyositis patients, from January 2014 to January 2017, hospitalized and treated with intravenous methylprednisolone repeated intermittent pulse combined with mycophenolate mofetil
Study Type
OBSERVATIONAL
Enrollment
12
investigate the clinical effectivity of intravenous methylprednisolone repeated intermittent pulse combined with mycophenolate mofetil in the treatment of newly diagnosed juvenile dermatomyositis
Change from baseline in CMAS score
CMAS score is an index to assess the disease activity of JDM
Time frame: 1, 3, 6, 12, 18, 24 and 36 months
Changes from baseline of the patient's height percentile in the same age and sex crowd.
the patient's height percentile in the same age and sex crowd is one of safety evaluation indicators.
Time frame: 1, 3, 6, 12, 18, 24 and 36months
Changes from baseline of the patient's weight percentile in the same age and sex crowd.
the patient's weight percentile in the same age and sex crowd is one of safety evaluation indicators.
Time frame: 1, 3, 6, 12, 18, 24 and 36months
intraocular pressure
the patient's intraocular pressure is one of safety evaluation indicators.
Time frame: 1, 3, 6, 12, 18, 24 and 36months
triglycerides
the patient's triglycerides is one of safety evaluation indicators.
Time frame: 1, 3, 6, 12, 18, 24 and 36months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.